{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:58:58Z","timestamp":1793404738131,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amgen GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Osteoporosis is the most common bone disorder. Our data gives an estimate of around 5.87 million cases of osteoporosis in the general German population in 2018. Only 30% of insured individuals who suffered an osteoporotic fracture and\/or had a confirmed diagnosis of osteoporosis, received an appropriate prescription.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Osteoporosis is the most common bone disorder. It particularly affects elderly people and increases the risk of atraumatic fractures. The aim of this study was to estimate the prevalence of osteoporosis in the general German population aged\u2009\u2265\u200950 years and to collect data on the frequency of prescription of osteoporosis-specific medication in order to assess the treatment gap.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective analysis of anonymized data of individuals aged\u2009\u2265\u200950 years insured under statutory healthcare schemes from the database of the Institute for Applied Health Research Berlin (InGef) for 2018 (study population). Insured individuals with osteoporosis were identified based on osteoporosis diagnoses, osteoporosis-specific prescriptions, or osteoporotic fractures. Thus, we estimated the prevalence of osteoporosis in the general German population aged\u2009\u2265\u200950 years. The prevalence of diagnoses, fractures, and prescriptions was determined for the study population and stratified by age and gender.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Within the study population of 1,599,299 insured individuals, a prevalence of osteoporosis of 15.9% was determined. This estimated approximately 5.87 million cases of osteoporosis for the general German population. 81.6% of the cases were women. Osteoporosis-specific prescriptions were received by 30.0% of the insured individuals in the study population who had been diagnosed with osteoporosis and\/or suffered an osteoporotic fracture.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Germany has a high prevalence of osteoporosis. Only a small portion of individuals who may require osteoporosis-specific treatment actually receive it.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11657-024-01380-9","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T12:02:34Z","timestamp":1712664154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Bone evaluation study-2: update on the epidemiology of osteoporosis in Germany"],"prefix":"10.1007","volume":"19","author":[{"given":"Peyman","family":"Hadji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Esterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Oberm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"1380_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","volume":"4","author":"T S\u00f6zen","year":"2017","unstructured":"S\u00f6zen T, \u00d6z\u0131\u015f\u0131k L, Ba\u015faran N (2017) An overview and management of osteoporosis. Eur J Rheumatol 4:46\u201356","journal-title":"Eur J Rheumatol"},{"key":"1380_CR2","first-page":"52","volume":"110","author":"P Hadji","year":"2013","unstructured":"Hadji P, Klein S, Gothe H, H\u00e4ussler B, Kless T, Schmidt T, Steinle T, Verheyen F, Linder R (2013) Epidemiologie der osteoporose \u2013 bone evaluation study. Dtsch Arztebl\u00a0Int 110:52\u201357","journal-title":"Dtsch Arztebl\u00a0Int"},{"key":"1380_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C, Borgstr\u00f6m F (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82","journal-title":"Arch Osteoporos"},{"key":"1380_CR4","doi-asserted-by":"publisher","unstructured":"Fuchs J, Scheidt-Nave C, Kuhnert R (2017) 12-Monats-Pr\u00e4valenz von osteoporose in Deutschland. J Health Monitoring pp 61\u201365. https:\/\/doi.org\/10.17886\/RKI-GBE-2017-054","DOI":"10.17886\/RKI-GBE-2017-054"},{"key":"1380_CR5","doi-asserted-by":"publisher","first-page":"882241","DOI":"10.3389\/fendo.2022.882241","volume":"13","author":"Y Shen","year":"2022","unstructured":"Shen Y, Huang X, Wu J et al (2022) The global burden of osteoporosis, low bone mass, and its related fracture in 204 countries and territories, 1990\u20132019. Front Endocrinol (Lausanne) 13:882241","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1380_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00198-020-05557-z","volume":"32","author":"E McCloskey","year":"2021","unstructured":"McCloskey E, Rathi J, Heijmans S et al (2021) The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporos Int 32:251\u2013259","journal-title":"Osteoporos Int"},{"key":"1380_CR7","unstructured":"Dachverband Osteologie e. V. (DVO): Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und bei M\u00e4nnern 2017. Leitline des Dachverbands Osteologie e. V; https:\/\/www.dv-osteologie.org\/uploads\/Leitlinie%202017\/Finale%20Version%20Leitlinie%20Osteoporose%202017_end.pdf. (abgerufen am 27 Apr 2022)"},{"key":"1380_CR8","unstructured":"Gemeinsamer Bundesausschuss: DMP f\u00fcr Osteoporose-Patienten beschlossen. Pressemitteilung Nr. 02 \/ 2020 vom 16. Januar 2020; https:\/\/www.g-ba.de\/presse\/pressemitteilungen-meldungen\/839\/. (abgerufen am 01 Aug 2022)"},{"key":"1380_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.puhe.2022.02.013","volume":"206","author":"M Ludwig","year":"2022","unstructured":"Ludwig M, Enders D, Basedow F, Walker J, Jacob J (2022) Sampling strategy, characteristics and representativeness of the InGef research database. Public Health 206:57\u201362","journal-title":"Public Health"},{"key":"1380_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11657-020-00800-w","volume":"15","author":"P Hadji","year":"2020","unstructured":"Hadji P, Hardtstock F, Wilke T, Joeres L, Toth E, M\u00f6ckel L, Gille P (2020) Estimated epidemiology of osteoporosis diagnoses and osteoporosis-related high fracture risk in Germany: a German claims data analysis. Arch Osteoporos 15:127","journal-title":"Arch Osteoporos"},{"issue":"3","key":"1380_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.17886\/RKI-GBE-2017-055","volume":"2","author":"J Fuchs","year":"2017","unstructured":"Fuchs J, Scheidt-Nave C, Kuhnert R (2017) 12-Monats-Pr\u00e4valenz von Osteoporose in Deutschland. Journal of Health Monitoring 2(3):61\u201365. https:\/\/doi.org\/10.17886\/RKI-GBE-2017-055","journal-title":"Journal of Health Monitoring"},{"key":"1380_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/GCO.0000000000000858","volume":"35","author":"N Shah","year":"2023","unstructured":"Shah N, Danit A (2023) The role of menopausal hormone therapy in the prevention and treatment of low bone density in perimenopausal and postmenopausal women. Curr Opin Obstet Gynecol 35:141\u2013149","journal-title":"Curr Opin Obstet Gynecol"},{"key":"1380_CR13","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s11154-022-09738-5","volume":"23","author":"K David","year":"2022","unstructured":"David K, Narinx N, Antonio L, Evenepoel P, Claessens F, Decallonne B, Vanderschueren D (2022) Bone health in ageing men. Rev Endocr Metab Disord 23:1173\u20131208","journal-title":"Rev Endocr Metab Disord"},{"key":"1380_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11684-020-0748-y","volume":"15","author":"X Zhu","year":"2021","unstructured":"Zhu X, Zheng H (2021) Factors influencing peak bone mass gain. Front Med 15:53\u201369","journal-title":"Front Med"},{"key":"1380_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11657-021-00915-8","volume":"16","author":"G Adami","year":"2021","unstructured":"Adami G, Gatti D, Rossini M, Giollo A, Bertoldo E, Viapiana O, Olivi P, Fassio A (2021) Factors associated with referral for osteoporosis care in men: a real-life study of a nationwide dataset. Arch Osteoporos 16:56","journal-title":"Arch Osteoporos"},{"key":"1380_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/1757975918816705","volume":"27","author":"A Holland","year":"2020","unstructured":"Holland A, Moffat T (2020) Gendered perceptions of osteoporosis: implications for youth prevention programs. Glob Health Promot 27:91\u201399","journal-title":"Glob Health Promot"},{"key":"1380_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S2213-8587(22)00012-2","volume":"10","author":"T Vilaca","year":"2022","unstructured":"Vilaca T, Eastell R, Schini M (2022) Osteoporosis in men Lancet Diabetes Endocrinol 10:273\u2013283","journal-title":"Osteoporosis in men Lancet Diabetes Endocrinol"},{"key":"1380_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00198-021-06051-w","volume":"33","author":"W B\u00f6cker","year":"2022","unstructured":"B\u00f6cker W, Doobaree IU, Khachatryan A, Dornstauder E, Bartsch R, Worth G, Singh M, Kahangire DA (2022) Fractures in untreated patients with osteoporosis in Germany: an InGef healthcare insurance database analysis. Osteoporos Int 33:77\u201386","journal-title":"Osteoporos Int"},{"key":"1380_CR19","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s00198-021-05881-y","volume":"32","author":"MM Delsmann","year":"2021","unstructured":"Delsmann MM, Strahl A, M\u00fchlenfeld M, Jandl NM, Beil FT, Ries C, Rolvien T (2021) High prevalence and undertreatment of osteoporosis in elderly patients undergoing total hip arthroplasty. Osteoporos Int 32:1661\u20131668","journal-title":"Osteoporos Int"},{"key":"1380_CR20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00198-021-06169-x","volume":"33","author":"MT L\u00f6ffler","year":"2022","unstructured":"L\u00f6ffler MT, Kallweit M, Niederreiter E, Baum T, Makowski MR, Zimmer C, Kirschke JS (2022) Epidemiology and reporting of osteoporotic vertebral fractures in patients with long-term hospital records based on routine clinical CT imaging. Osteoporos Int 33:685\u2013694","journal-title":"Osteoporos Int"},{"key":"1380_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/8756-3282(88)90009-9","volume":"9","author":"S Phillips","year":"1988","unstructured":"Phillips S, Fox N, Jacobs J, Wright WE (1988) The direct medical costs of osteoporosis for American women aged 45 and older, 1986. Bone 9:271\u2013279","journal-title":"Bone"},{"key":"1380_CR22","first-page":"44","volume":"8","author":"L Pientka","year":"1996","unstructured":"Pientka L (1996) Die \u00f6konomische Be-deutung der Osteoporose in Deutschland. Der Kassenarzt 8:44\u201352","journal-title":"Der Kassenarzt"}],"updated-by":[{"DOI":"10.1007\/s11657-024-01388-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000}}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-024-01380-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-024-01380-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-024-01380-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T12:05:41Z","timestamp":1734350741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-024-01380-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1380"],"URL":"https:\/\/doi.org\/10.1007\/s11657-024-01380-9","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]},"assertion":[{"value":"1 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11657-024-01388-1","URL":"https:\/\/doi.org\/10.1007\/s11657-024-01388-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript was created with the assistance of a medical writer, a graphic designer and two editors. These services were funded by Amgen, Germany. PH received fees for consulting and speaking from Amgen Ltd, Elli Lilly, Gedeon Richter, Hexal, Stada, Theramex and UCB. EE is employed by RTI Health Solutions, an independent non-profit organization that received financial support from Amgen to conduct this study. DO is an employee of InGef, which received financial support from RTI Health Solutions to conduct this study. RB is an employee of Amgen and holds stocks in Amgen Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"26"}}